Filing Details

Accession Number:
0000935836-25-000197
Form Type:
13G Filing
Publication Date:
2025-02-24 19:00:00
Filed By:
Stonepine Capital
Company:
Edesa Biotech Inc. (OTCMKTS:EDSA)
Filing Date:
2025-02-25
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Stonepine Capital Management, LLC 0 693,551 9.9%
Stonepine Capital, L.P. 0 693,551 9.9%
Stonepine GP, LLC 0 693,551 9.9%
Jon M. Plexico 0 693,551 9.9%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  Percentage calculated based on (a) (1) 687,500 shares of Common Stock beneficially owned by the reporting person, and (2) 93,750 shares of Common Stock issuable on conversion of 18 shares of Series B-1 Convertible Preferred Stock beneficially owned by the reporting person, subject to a 9.99% beneficial ownership limitation, and (b) 6,936,404 shares of Common Stock outstanding on February 14, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended December 31, 2024.


SCHEDULE 13G



Comment for Type of Reporting Person:  Percentage calculated based on (a) (1) 687,500 shares of Common Stock beneficially owned by the reporting person, and (2) 93,750 shares of Common Stock issuable on conversion of 18 shares of Series B-1 Convertible Preferred Stock beneficially owned by the reporting person, subject to a 9.99% beneficial ownership limitation, and (b) 6,936,404 shares of Common Stock outstanding on February 14, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended December 31, 2024.


SCHEDULE 13G



Comment for Type of Reporting Person:  Percentage calculated based on (a) (1) 687,500 shares of Common Stock beneficially owned by the reporting person, and (2) 93,750 shares of Common Stock issuable on conversion of 18 shares of Series B-1 Convertible Preferred Stock beneficially owned by the reporting person, subject to a 9.99% beneficial ownership limitation, and (b) 6,936,404 shares of Common Stock outstanding on February 14, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended December 31, 2024.


SCHEDULE 13G



Comment for Type of Reporting Person:  Percentage calculated based on (a) (1) 687,500 shares of Common Stock beneficially owned by the reporting person, and (2) 93,750 shares of Common Stock issuable on conversion of 18 shares of Series B-1 Convertible Preferred Stock beneficially owned by the reporting person, subject to a 9.99% beneficial ownership limitation, and (b) 6,936,404 shares of Common Stock outstanding on February 14, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended December 31, 2024.


SCHEDULE 13G


 
Stonepine Capital Management, LLC
 
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member
Date:02/25/2025
 
Stonepine Capital, L.P.
 
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member of the General Partner, Stonepine GP, LLC
Date:02/25/2025
 
Stonepine GP, LLC
 
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member
Date:02/25/2025
 
Jon M. Plexico
 
Signature:/s/ Jon M. Plexico
Name/Title:Reporting person
Date:02/25/2025
Exhibit Information

Exhibit 99 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G